2nd Annual Alavi Bradley Symposium

Tuesday, September 19, 2023, 8:00 AM - 4:45 PM, SMC Campus Center, Baltimore, MD

1. At the conclusion of this activity, participants will be able to:
2. 1. To understand precision imaging and how it is different from conventional clinical radiology
3. 2. To utilize imaging as a platform for translation
4. 3. To understand current trends in imaging research, with a focus on molecular imaging
5. 4. Familiarizing audience with A-Brillouin scattering phenomenon; B-Corresponding instrnmentation; C-Corresponding signatures and uses in cancer biology
6. 5. Understand the hallmarks of a vulnerable atherosclerotic plaque
7. 6. Learn about 18F-FDG PET for imaging plaque inflammation
8. 7. Learn about 18F-NaF PET for imaging plaque micro calcification
9. 8. Understand why Fl8-MFBG PET/CT is a better imaging modality than I-123 MIBG study in the evaluation of patients with neuroblastoma
10. 9. Knowing the utility of F18-MFBG PET/CT in comparison to I-123 MIBG SPECT/CT
11. 10. Knowing the utility of Fl 8-MFBG PET/CT in the evaluation of metastatic pheochromocytoma/paragangliomas

The University of Maryland School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Maryland School of Medicine designates this Live activity for a maximum of 5.00 AMA PRA Category 1 Credits ^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMA PRA Category 1 Credits™ (5.00 hours), Non-Physician Attendance (5.00 hours)

You are not logged in.

Please click the button below to login or create a new account before continuing.

Mitigation of Relevant Financial Relationships

University of Maryland School of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

No faculty are available for this activity at this time.